-
Product Insights
Systemic Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Candidiasis - Drugs In Development, 2023’, provides an overview of the Systemic Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Meningitis - Drugs In Development, 2023’, provides an overview of the Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Candidiasis - Drugs In Development, 2023’, provides an overview of the Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1598 in Coccidioidomycosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VT-1598 in Coccidioidomycosis Drug Details: VT-1598 was under development for the treatment of invasive fungal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HUC-3431 in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HUC-3431 in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HUC-3431 in Hypercholesterolemia Drug Details: HUC3-431 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1598 in Cryptococcal Meningitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VT-1598 in Cryptococcal Meningitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VT-1598 in Cryptococcal MeningitisDrug Details:VT-1598 is under development for the treatment of invasive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oteseconazole in Onychomycosis (Tinea Unguium)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oteseconazole in Onychomycosis (Tinea Unguium) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Oteseconazole in Onychomycosis (Tinea Unguium) Drug Details: Oteseconazole (Vivjoa) is a potent...